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 Background Senescent cells, which express p16INK4a, accumulate with aging and contribute to age-related pathology. To 
understand whether cytotoxic agents promote molecular aging, we measured expression of p16INK4a and other 
senescence markers in breast cancer patients treated with adjuvant chemotherapy.
 Methods Blood and clinical information were prospectively obtained from 33 women with stage I  to III breast cancer 
at four time points: before anthracycline-based chemotherapy, immediately after anthracycline-based chemo-
therapy, 3  months after anthracycline-based chemotherapy, and 12  months after anthracycline-based chemo-
therapy. Expression of senescence markers p16INK4a and ARF mRNA was determined using TaqMan quantitative 
reverse-transcription polymerase chain reaction in CD3+ T lymphocytes, telomere length was determined by 
Southern analysis, and senescence-associated cytokines were determined by enzyme-linked immunosorbent 
assay. Findings were independently assessed in a cross-sectional cohort of 176 breast cancer survivors enrolled 
a median of 3.4 years after treatment; 39% previously received chemotherapy. All statistical tests were two-sided.
 Results In prospectively analyzed patients, expression of p16INK4a and ARF increased immediately after chemother-
apy and remained elevated 12 months after treatment. Median increase in log2p16INK4a was 0.81 (interquartile 
range = 0.28–1.62; Wilcoxon signed-rank P < .001), or a 75% absolute increase in expression, equivalent to the 
increase observed over 14.7 years of chronological aging. ARF expression was comparably increased (P < .001). 
Increased expression of p16INK4a and ARF was associated with dose-dense therapy and hematological toxicity. 
Expression of two senescence-associated cytokines (VEGFA and MCP1) was durably increased by adjuvant chem-
otherapy. Telomere length was not affected by chemotherapy. In a cross-sectional cohort, prior chemotherapy 
exposure was independently associated with a log2-increase in p16INK4a expression of 0.57 (repeated measures 
model, P < .001), comparable with 10.4 years of chronological aging.
 Conclusions Adjuvant chemotherapy for breast cancer is gerontogenic, inducing cellular senescence in vivo, thereby acceler-
ating molecular aging of hematopoietic tissues.
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With the aging of the American population, the incidence of new 
cancer diagnoses is projected to increase 45% from 2010 to 2030 
(1). Coupled with the growing proportion of cancer patients who 
are cured (2), we face a new challenge: a large population of aging 
cancer survivors (3). Long-term survivors of childhood and adult 
cancer can exhibit substantial late sequelae, including endocrine 
dysfunction, cognitive impairment, cardiovascular morbidity, sec-
ondary neoplasms, and neuromuscular impairment (4–8). Little is 
known about how chemotherapy causes long-term adverse effects 
and whether it alters the pace of physiologic aging.
Human aging is characterized by a steady decline in organ 
function, which leads to loss of physiologic reserve and frailty (9). 
This loss of function is characterized by a decline in the replicative 
capacity of certain self-renewing cells and the accumulation of cells 
that have undergone cellular senescence (10,11). Cellular senes-
cence is triggered by the activation of tumor-suppressor mecha-
nisms in response to varied cellular stresses such as oncogene 
activation, tissue injury, telomere dysfunction, and persistent DNA 
damage. Senescence is strongly associated with activation of the 
INK4/ARF (CDKN2a) locus on human chromosome 9p21.3, which 
encodes the p16INK4a and ARF tumor suppressor proteins. Several 
lines of evidence suggest senescence influences mammalian aging: 
1) expression of p16INK4a increases exponentially with chronological 
aging (12–14) and causes reduced replicative capacity of some cell 
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types (15–19); 2) regulatory polymorphisms of senescence regula-
tors (eg, CDKN2a and TERT) have been linked through unbiased 
genome-wide studies with many age-associated conditions such 
as cancer, pulmonary fibrosis, atherosclerosis, and type II diabetes 
(20); and 3) therapies to decrease the production of or increase the 
clearance of senescent cells in mice ameliorate certain age-associ-
ated phenotypes (21–23).
Because of the intimate links between senescence and aging, 
markers of cellular senescence, including leukocyte telomere 
length (LTL), expression of senescence-associated (SA) cytokines 
such as interleukin 6 (IL-6), and expression of INK4a/ARF tran-
scripts, have been tested as potential biomarkers of molecular 
aging. Decreased LTL has been linked with chronological age and 
age-promoting stressors such as cigarette smoking in several stud-
ies in human populations (24–26). Senescent cells elaborate a host 
of potent cytokines (ie, the senescence-associated secretory pheno-
type) (27), which promote a proinflammatory tissue microenviron-
ment. Expression of SA-cytokines, such as IL-6, has been reported 
to increase with aging and to predict age-associated morbidities 
and mortality (28–32). More recently, expression of p16INK4a, and to 
a lesser extent ARF, in defined tissues such as peripheral blood T 
cells (PBTLs) have been described as biomarkers of aging. Using 
the p16INK4a assay, we have shown that smoking, physical inactiv-
ity, and chronic human immunodeficiency virus infection accel-
erate expression of this biomarker of molecular age in the PBTL 
compartment (14,33). Given the apparent long-term toxicities of 
DNA-damaging agents, we sought to determine whether cytotoxic 




Human studies were approved by the University of North Carolina 
Institutional Review Board (08-0823; 09-2344). All patients gave 
written informed consent before undergoing any study-related 
procedures. The adjuvant cohort (LCCC0810) (Figure  1A) con-
sisted of women with newly diagnosed American Joint Committee 
on Cancer 6th edition (34) stage I  to III breast cancer planning 
to receive either neoadjuvant or adjuvant anthracycline-contain-
ing chemotherapy. Women were consented before treatment to 
undergo phlebotomy before chemotherapy, at count recovery 
immediately after chemotherapy, and at their 3- and 12  month 
regularly scheduled visits. Patients with prior pelvic radiation or a 
clonal bone marrow disorder were excluded.
The survivor cohort (LCCC0924) (Figure  1B) consisted 
of women aged 50 years and older with a history of a surgically 
resected stage I to III breast cancer. Those who had received chem-
otherapy needed to enroll at least 3 months from completion of 
chemotherapy. Those taking endocrine therapy were eligible after 
3  months of treatment. Women with recurrent cancer, a clonal 
bone marrow disorder, or a life expectancy less than 12  months 
were excluded. A  single sample was obtained from women in 
the survivor cohort at time of consent. Women in both cohorts 
received standard-of-care chemotherapy regimens or treatment on 
institutional review board–approved clinical trials. Standard-of-
care chest wall radiotherapy and adjuvant hormonal therapy were 
given as clinically indicated. Health behaviors and demographics 
were evaluated by patient questionnaire. Medical history and treat-
ment were extracted from the medical record. For each time point, 
a single lavender (EDTA) tube (5–10 mL) was collected and placed 
immediately on ice. Molecular and serologic analyses were per-
formed by investigators blinded to patient data, and investigators 
collecting clinical information were blinded to laboratory results 
until data collection was complete.
Analysis of INK4a/ARF Expression, Telomere Length, and 
SA-Cytokine Expression
Analysis of p16INK4a and ARF expression in CD3+ PBTLs was 
performed as described (14,33). In brief, on the day of collec-
tion, PBTLs were isolated using anti-CD3 microbeads and an 
AutoMACSPRO separator (Miltenyi Biotec, San Diego, CA). Total 
RNA and cDNA were prepared (14,33), followed by TaqMan 
quantitative reverse-transcription polymerase chain reaction spe-
cific for p16INK4a (exon 1alpha-exon 2; custom order ID: AII1L5T; 
Life Technologies USA, Carlsbad, CA) or ARF (exon 1beta-exon 2; 
custom assay order ID: AIKAKB1; Life Technologies USA) with 
normalization to 18S housekeeping gene (order number 4352655; 
Life Technologies USA). Using this method, 15.4% of samples in 
the adjuvant cohort and 16.2% of samples in the survivor cohort 
failed analysis because of sorting failure, insufficient nucleic acid 
yield, poor quality RNA, or failure to pass a data replicate filter 
(Figure 1; see also Supplementary Methods, available online, for 
details). There was no statistically significant difference in age 
between patients whose samples failed analysis and patients with 
results who were included in either cohort. Expression of p16INK4a 
with aging in reporter mice was assayed as described (see also 
Supplementary Methods, available online) (35).
Analysis of senescence-associated cytokines and LTL was 
performed on patient sera collected before and 12 months after 
chemotherapy in the adjuvant cohort (in 3 patients without a 
12-month sample, the 3-month sample was used). Analysis of 
vascular endothelial growth factor A  (VEGFA; R&D systems 
DVE00, Minneapolis, MN), IL-6 (R&D systems LUH206), 
interleukin 7 (IL-7; R&D systems HS750), interleukin 8 (IL-8; 
R&D systems LUH208) and monocyte chemotactic protein-1 
(MCP1, also referred to as chemokine CCL2; R&D systems 
DCP00) was performed by enzyme-linked immunosorbent assay. 
IL-6 was detectable before and after chemotherapy in only three 
patients; therefore it was not further analyzed. LTL was meas-
ured by Southern analysis as described (36).
p16INK4a Expression With Reporter Mice
All murine studies were done under a protocol approved by the 
University of North Carolina Institutional Animal Care and Use 
Committee. Albino hairless SKH1-E p16+/Luc mice developed in the 
Sharpless lab at the University of North Carolina as described in Burd 
et al. (35) were serially housed in the University of North Carolina 
LCCC Mouse Phase I Unit. A cohort of 32 female mice were aged (6, 
23, 55, and 73 weeks) and imaged. This was repeated five times with 
different sets of mice from this cohort. Animals were imaged using an 
IVIS LUMINA imaging system (PerkinElmer, Waltham, MA). The 
image shown is a 2-minute exposure taken 8 minutes after luciferin 
injection. For the full protocol, see Burd et al. (35).
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Statistical Analysis
In brief (see Supplementary Methods, available online, for addi-
tional details), because p16INK4a and ARF expression increase 
exponentially with age (14,37), results were logarithmically trans-
formed. For the adjuvant cohort, change in INK4a/ARF expression, 
SA-cytokine, and LTL from baseline to post-treatment time points 
were compared overall and across age strata using the Wilcoxon 
signed-rank, rank-sum, and Kruskal–Wallis tests. Because each 
woman had at least one post-treatment sample, to maximize sample 
size we used the average post-treatment p16INK4a and ARF expression 
to test for association of clinical factors with magnitude of change 
in expression. In the survivor cohort, p16INK4a was measured twice 
in all patients. Rather than arbitrarily choose a single or mean value 
for each patient, we assumed that measures within a batch were not 
independent, and thus multivariable repeated measures models, 
which account for this nonindependence, were used to evaluate the 
association between clinical factors and p16INK4a expression. ARF 
expression was measured in a single batch and analyzed by linear 
regression. Predicted p16INK4a for age according to prior treatment 
is shown graphically. In both cohorts, the association between age, 
race, and key clinical factors with p16INK4a expression was evalu-
ated. Results for the Adjuvant cohort are shown in Supplementary 
Table 1 (available online). In the survivor cohort, few clinical fac-
tors were associated with expression; therefore only factors either 
Figure 1. Cohort assembly. The consort diagram for LCCC0810, the adju-
vant cohort (A) shows number of evaluable patients at each time point. 
Thirty-nine women consented to participation. Results from the base-
line sample were not available for six of the 39 patients. These six could 
not be included in the paired analysis; thus the analytic cohort is com-
prised of the 33 women for whom baseline results are available. All 33 
women had at least one post-treatment sample collected. Fourteen had 
results at all post-treatment points, 11 were missing one time point, and 
8 were missing two time points. The consort diagram for LCCC0924, the 
survivor cohort (B) shows 34 of 210 evaluable patients were excluded 
because of sorting or RNA failure (see Supplementary Methods, avail-
able online). AC = doxorubicin and cyclophosphamide.
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statistically significantly associated with expression or of key clini-
cal relevance were included in multivariable models. Data were 
analyzed by H. K. Sanoff, A. M. Deal, and J. G. Ibrahim using SAS 
version 9.2 (SAS, Cary, NC) and STATA version 12 (StataCorp, 
College Station, TX). To quantitate the age-promoting effects of 
chemotherapy, the fold-change in p16INK4a expression induced by 
chemotherapy was compared with the effect of chronologic aging 
on p16INK4a in healthy donors from previously published, independ-
ent cohorts (14,35).
All tests of statistical significance were two-sided. P values of .05 
or less were considered statistically significant.
results
To test the hypothesis that chemotherapy accelerates the activation 
of cellular senescence in vivo, we measured expression of senes-
cence markers in two cohorts of women with breast cancer treated 
with curative intent.
The prospective adjuvant cohort consisted of 33 women, with 
a median age of 49 years (range = 32–69) (Table 1; Supplementary 
Table 1, available online). The women had few comorbid condi-
tions, although nearly half were obese (body mass index ≥30 kg/m2; 
n = 15; 45.5%). The majority (n = 29) of women received adjuvant 
doxorubicin and cyclophosphamide and a taxane. Most women 
(n = 27; 81.8%) received adjuvant doxorubicin and cyclophospha-
mide in a dose-dense fashion (38). Baseline p16INKa and ARF expres-
sion were not associated with age in this small sample with narrow 
age range (Supplementary Table 1, available online).
In the adjuvant cohort, chemotherapy led to a statistically sig-
nificant and persistent rise in both p16INKa and ARF expression at 
all post-treatment time points (Figure 2; Supplementary Table 2, 
available online). Expression of p16INK4a decreased with chemother-
apy in only one patient, who was later found to have congenital p53 
deficiency (Li-Fraumeni syndrome; see Supplementary Methods, 
available online). In the entire cohort, a median increase in the log-
2p16INKa expression of 0.81 (interquartile range [IQR] = 0.28–1.62; 
Wilcoxon signed-rank P < .001) and in the log2ARF expression of 
0.89 (IQR = 0.29–1.27; Wilcoxon signed-rank P < .001) was seen 
from baseline to the average post-treatment value. In non-log-
transformed terms, this reflects median increases of 75% and 85% 
in p16INK4a and ARF, respectively. Using a murine reporter system 
(Supplementary Figure 1, available online) and in prior studies of 
normal human volunteers (14,35), we have noted a characteristic 
exponential increase in p16INK4a expression with aging that is asso-
ciated with species’ lifespans. In independent cohorts of healthy 
human donors, log2p16INKa exhibits a mean increase of 0.055 units 
per year (or 4% per year) (14,35). Therefore, the increase in 
PBTL p16INK4a expression associated with adjuvant breast cancer 
chemotherapy is equivalent to increases seen with 14.7  years of 
chronological aging.
Cytotoxic chemotherapy also increased the in vivo levels 
of other markers of senescence. Plasma concentrations of two 
SA-cytokines, VEGFA and MCP1/CCL2 (27,39), were statisti-
cally significantly increased in postchemotherapy compared with 
prechemotherapy samples (median VEGFA  =  118 vs 80 pg/mL, 
Wilcoxon signed-rank P  =  .001; median MCP1/CCL2  =  166 vs 
117 pg/mL, Wilcoxon signed-rank P < .001). Expression of other 
senescence markers (eg, IL-7, IL-8, and LTL) (Supplementary 
Figure 2, available online) did not statistically significantly change 
after chemotherapy. These data suggest that cytotoxic chemother-
apy increases expression of transcriptional senescence markers in 
Table 1. Patient and treatment characteristics*






Age, y, median (range) 49 (32–69) 67 (50–93)
  <50 17 (51.5%) 0
  50–64 12 (36.4%) 63 (35.8%)
  65–74 4 (12.1%) 80 (45.5%)
  ≥75 0 33 (18.8%)
Race/ethnicity
  White 26 (78.8%) 148 (84.1%)
  Black 7 (21.2%) 26 (14.8%)
  Asian/Other 0 2 (1.1%)
Comorbidities
  Diabetes 5 (15.2%) 24 (13.9%)
  Coronary heart disease 0 6 (3.5%)
  Stroke 0 4 (2.3%)
 BMI, kg/m2, median (range) 29 (18–50) 28 (18–58)
  <18.5, underweight 1 (3.0%) 1 (0.6%)
  18.5–24.9, normal 6 (18.2%) 59 (33.5%)
  25.0–29.9, overweight 11 (33.3%) 55 (31.3%)
  ≥30, obese 15 (45.5%) 61 (34.7%)
Smoking
  Never 20 (62.5%) 102 (58.3%)
  Former 7 (21.9%) 63 (36.0%)
  Current 5 (15.6%) 10 (5.7%)
AJCC summary stage† Not collected
  Stage I 6 (18.2%) —
  Stage II 18 (54.5%) —
  Stage III 9 (27.3%) —
ER or ER/PR positive 20 (60.6%) —
HER2 positive 7 (21.2%) —
Triple-negative 9 (27.3%) —
Adjuvant radiotherapy 25 (75.8%) 103 (58.5%)
Adjuvant hormonal therapy 20 (60.6%) 124 (70.5%)
Adjuvant chemotherapy 33 (100%) 69 (39.2%)
  AC 3 (9.4%) 12 (17.4%)
  AC → T 29 (87.9%)‡ 41 (59.4%)§
  TC 0 9 (13.0%)
  CMF 0 3 (4.3%)
  Other|| 1 (3.0%) 4 (5.8%)
Years from chemotherapy,  
median (range)
NA 3.4 (0.3–18. 8)
* Data are No. (%) unless otherwise noted. AC = doxorubicin and 
cyclophosphamide; AJCC = American Joint Committee on Cancer; 
BMI = body mass index; CMF = cyclophosphamide, methotrexate, 
5-fluorouracil; HER2 = human epidermal growth factor receptor 2; 
ER = estrogen receptor; PR = progesterone receptor; T = paclitaxel; 
TC = docetaxel and cyclophosphamide.
† Ten women were treated neoadjuvantly; summary stage is pretreatment 
clinical stage. For the 23 adjuvantly treated women, summary stage is the 
pathological stage. Stage, ER/PR, and HER2 could not be confirmed from 
pathology reports for the survivor cohort.
‡ One woman received nab-paclitaxel.
§ One woman received 2 AC/2 TC; one women received docetaxel instead 
of paclitaxel; two women received capecitabine after completing AC-T; one 
woman received post-AC+T bevacizumab and metronomic chemotherapy.
|| One woman in the adjuvant cohort received fluorouracil, epirubicin, 
cyclophosphamide. One woman in the survivor cohort received navelbine 
only, and three women in the survivor cohort received paclitaxel only.
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PBTLs, as well as serologic levels of two well-described secreted 
markers of senescence activation.
We also considered as secondary endpoints the effect of other 
treatment-related factors on change in PBTL p16INK4a expression 
with cytotoxic chemotherapy. Neither adjuvant chest wall radio-
therapy (n = 25) nor taxane use (n = 29) was independently associated 
with change in p16INK4a expression, although caution is warranted 
given the small number of patients. Dose-dense (every 2 weeks) 
chemotherapy was associated with a greater rise in log2p16INKa than 
a standard schedule of adjuvant doxorubicin and cyclophosphamide 
every 3 weeks (median = 1.13 vs 0.32; Wilcoxon rank-sum P = .04) 
(Supplementary Figure 3, available online). A trend toward greater 
median change in p16INKa expression was observed in women expe-
riencing grade 3 and 4 hematologic toxicity than in women without 
severe hematologic toxicity (median = 1.31 vs 0.57; Wilcoxon rank-
sum P  =  .07). These results suggest that more intensive chemo-
therapy and more severe myelosuppression are associated with a 
greater acceleration of molecular age in hematopoietic tissues.
Given the statistically significant induction of p16INK4a for up to 
1 year after chemotherapy (Figure 2A), we examined the effect of 
cytotoxic chemotherapy on p16INK4a expression at later time points 
in an independent cross-sectional survivor cohort (Figure 1B and 
Table 1). Of the 176 evaluable breast cancer survivors, 69 (39.2%) 
had received adjuvant chemotherapy. In this cohort, smoking, 
comorbidity, and body mass index were not independently asso-
ciated with p16INK4a expression. Age was statistically significantly 
associated with p16INK4a expression, with an estimated p16INK4a dou-
bling time of 16.7 years (ie, a 0.06 unit per year increase in log-
2p16INK4a; repeated measures model P < .001). In adjusted analyses, 
log2p16INK4a expression in chemotherapy-treated women was 0.57 
higher (repeated measures model P < .001)  than in women not 
treated with chemotherapy. Compared with the increase seen in 
independent cohorts of healthy human donors [0.055 per year (14, 
35)], this increase is equivalent to 10.4 years of chronological aging 
(Figure 3). ARF expression was not statistically significantly associ-
ated with prior chemotherapy use in the survivor cohort. As in the 
adjuvant cohort, chest wall radiotherapy and adjuvant hormonal 
therapy were not independently associated with p16INK4a expression 
(Supplementary Table 3, available online). Because patients in this 
cohort were a median 3.4  years from the completion of chemo-
therapy (some up to 18 years from treatment), these results sug-
gest that the sharp increase in p16INK4a expression observed after 
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Figure  2. Chemotherapy-induced increase in p16INK4a and ARF 
expression in the prospective adjuvant cohort. Mean values (dots) 
with 95% confidence intervals (dotted lines) of log2p16INK4a (A) 
and log2ARF (B) from pretreatment through three post-treatment 
time points: immediately upon count recovery after chemother-
apy and 3  months and 12  months after chemotherapy. The change 
from pretreatment (Pre) to the average post-treatment (Post avg) 
value is shown for individual patients for log2p16INK4a (median 
change = 0.81; interquartile range [IQR] = 0.28–1.62; Wilcoxon signed-
rank P < .001) (C) and log2ARF (median change = 0.89; IQR = 0.29–
1.27; Wilcoxon signed-rank P < .001) (D). All statistical tests were 
two-sided.
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chemotherapy persists for at least several years, if not indefinitely, 
after chemotherapy exposure.
Discussion
We have shown that adjuvant breast cancer chemotherapy leads to 
a substantial increase in molecular markers of cellular senescence, 
including CDKN2a expression in PBTLs, as well as serologic lev-
els of two senescence-associated cytokines. In these prospectively 
followed patients treated with standard adjuvant chemotherapy, a 
near doubling of p16INK4a and ARF expression was seen in T cells 
after adjuvant doxorubicin and cyclophosphamide chemotherapy, 
an increase comparable to 14.7  years of normal chronological 
aging (14,35). More aggressive dose-dense chemotherapy sched-
ules and greater hematologic toxicity were associated with a greater 
in vivo induction of markers of cellular senescence. The effect of 
chemotherapy on p16INK4a expression was confirmed in an inde-
pendent, cross-sectional cohort of long-term breast cancer survi-
vors. In aggregate, results from these two analyses demonstrate that 
adjuvant cytotoxic chemotherapy durably promotes expression of 
markers of cellular senescence in breast cancer patients.
The principal limitation of this study is the reliance on markers 
that can be only easily assayed in the peripheral blood. Although 
data from both cohorts showed an increase in p16INK4a expres-
sion after systemic chemotherapy, we can only conclusively state 
that chemotherapy promotes expression of senescence markers in 
CD3+ lymphocytes. Age-related increases in p16INK4a expression 
occur across a wide variety of mammalian tissue compartments 
(Supplementary Figure 1, available online) (see also [12,13,35,40)], 
yet the amplitude of age-related change varies by tissue compart-
ment as does its response to interventions that modify aging such 
as caloric restriction (13). Likewise, the tissue source of increased 
senescence-associated cytokines after chemotherapy is unknown. 
Thus, it is uncertain whether measurement of senescence-associ-
ated cytokines or p16INK4a expression in a hematopoietic compart-
ment can serve as a proxy for generalized organismal age, and our 
data do not speak to the pro-aging effects of chemotherapy in non-
hematopoietic compartments.
We were able to reproducibly show that breast cancer chemo-
therapy leads to a durable increase in PBTL p16INK4a expression, 
but we were unable to show an effect of chemotherapy on LTL and 
IL-6. Both of these biomarkers have been extensively studied as 
aging biomarkers, and unequivocally change (decrease for LTL and 
increase for IL-6) across the lifespan when measured in large popu-
lations (24–26,41). However, neither assay is well suited for indi-
vidual risk prediction: the absolute level/length vary substantially 
among same-aged individuals, and the absolute change is relatively 
small over an individual’s lifespan (24,32,41–43). Longitudinal stud-
ies of LTL have shown an expected annual decrease in length of 25 
to 45 base pairs, although 15% to 20% of prospectively followed 
people demonstrated telomere elongation over the studied period 
(41). Such variation has also been observed in studies of patients 
receiving chemotherapy (44,45). This wide variation in individual 
LTL over time in concert with the finding that administration of 
granulocyte colony stimulating factor may increase LTL through 
upregulation of telomerase (46,47), suggest LTL is unlikely to be 
a reliable biomarker of the effect of chemotherapy on molecular 
aging. Further, others have shown that the chemotherapy-induced 
cellular senescence in a variety of cancer cell lines and murine 
models is independent of telomere length and telomerase activity, 
suggesting LTL is a poor marker of chemotherapy-induced aging 
[reviewed in (48)]. Likewise IL-6 is suboptimal for this purpose 
because baseline expression is low but shows substantial age-inde-
pendent confounding from circadian variation and induction by 
viral infection and other stressors (32,49). We believe that p16INK4a 
expression in PBTLs offers new potential as a diagnostic marker 






























Figure  3. Expression of p16INK4a and ARF by age and prior chemo-
therapy exposure in the cross-sectional survivor cohort. Log2p16INK4a 
(A) and log2ARF (B) at each age according to receipt of adjuvant ther-
apy. Dots represent the average value for each patient among the three 
batches. Lines represent the predicted values for chemotherapy-treated 
(red) and non-chemotherapy-treated (blue) patients based on the results 
of the repeated measures models. Log2p16INK4a is statistically signifi-
cantly higher in chemotherapy-treated vs non-chemotherapy-treated 
patients (repeated measures model P < .001). Log2ARF is not statisti-
cally significantly higher in chemotherapy-treated patients vs non-
chemotherapy-treated patients (linear regression model P  =  .10). All 
statistical tests were two-sided.
Vol. 106, Issue 4 | dju057 | April 9, 20147 of 8 Article | JNCI
of senescence induction in vivo given its very large dynamic range 
(approximately 16-fold change over a human lifespan), ease and 
low cost of measure, and strong correlation with chronological age 
(R2 with chronological age is approximately 0.6 for p16INK4a vs <0.2 
for LTL or IL-6) (14,26,41,42).
Based on murine analyses, we believe the PBTL increase in 
p16INK4a expression likely reflects heritable damage to hematopoi-
etic stem cells (17,50) but may also reflect damage to the thymic 
milieu (21) or direct damage to self-renewing, post-thymic T cells 
(18). Adjuvant anthracycline-based chemotherapy unequivocally 
saves lives, markedly decreasing the relative risk of breast cancer 
recurrence by 27% and death by 21% (51). Therefore, we believe 
the finding of durable, age-promoting effects of anthracyclines 
and alkylating agents must be weighed against these established 
benefits with regard to relapse risk. The ability to serially measure 
markers of molecular age in patients may provide a means to iden-
tify beneficial adjuvant approaches that are less “pro-aging.” For 
example, these results suggest that dose-dense therapy may induce 
greater long-term hematologic damage, whereas taxanes may be 
associated with less long-term risk. Further work to more directly 
quantify the contribution of each component of adjuvant therapy 
on certain known long-term sequelae may allow for more balanced 
treatment decisions and perhaps greater use of less gerontogenic 
regimens for low-risk cancers.
In summary, we have shown that cytotoxic chemotherapy 
potently induces the expression of markers of cellular senescence in 
the hematologic compartment in vivo, comparable with the effects 
of 10 to 15 years of chronologic aging in independent cohorts of 
healthy donors. We are currently enrolling in two prospective tri-
als: one evaluating whether changing PBTL p16INK4a expression is 
a biomarker of acute toxicity of various chemotherapy regimens 
(LCCC1027, NCT01305954); and a second focused exclusively on 
older patients evaluating the combination of a validated geriatric 
assessment and PBTL p16INK4a for prediction of treatment-related 
toxicity and change in function (NCT01472094). Although refin-
ing the clinical utility of this biomarker of molecular aging will 
take further study, we have shown that chemotherapy accelerates 
molecular aging in the hematopoietic compartment of breast can-
cer survivors.
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